Walter M. Stadler to Cisplatin
This is a "connection" page, showing publications Walter M. Stadler has written about Cisplatin.
Connection Strength
1.440
-
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002 Jul-Aug; 7(4):153-7.
Score: 0.181
-
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002 Jan; 13(1):116-20.
Score: 0.175
-
Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32.
Score: 0.166
-
Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 2018 07; 11(4):420-427.
Score: 0.135
-
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517.
Score: 0.117
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.109
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.085
-
A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4.
Score: 0.055
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
Score: 0.050
-
Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3.
Score: 0.048
-
Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
Score: 0.044
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
Score: 0.042
-
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7.
Score: 0.039
-
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol. 1999; 44(1):81-7.
Score: 0.036
-
[New chemotherapy regimens for advanced bladder cancer]. Actas Urol Esp. 1998 Jun; 22(6):548-9.
Score: 0.034
-
New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9.
Score: 0.033
-
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
Score: 0.023
-
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20; 29(12):1525-30.
Score: 0.021
-
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
Score: 0.018
-
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4.
Score: 0.015
-
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13.
Score: 0.014